Crucell ends PER.C6 patent infringement case as Cevec agrees not to misuse cell bank

By E. Janene Geiss

Philadelphia, May 9 - Crucell NV said Tuesday the patent infringement proceedings before the Düsseldorf District court against Cevec Pharmaceuticals GmbH have been settled with Crucell withdrawing one remaining claim as part of the court settlement.

The claim sought destruction of a N52E6 cell bank made prior to the grant of Crucell's European PER.C6 patent that resides outside the jurisdiction of the Düsseldorf court, but is still under the control of Cevec, according to a company news release.

The withdrawal of the claim follows Cevec's commitment that it will not use, nor grant permission to use the cell bank in the future in any way that infringes Crucell's PER.C6 patent.

The infringement of the N52E6 cells in Germany subsequent to the grant of Crucell's PER.C6 patent had already been acknowledged by the Düsseldorf court on Dec. 14, 2004.

Crucell is a biotechnology company based in Leiden, The Netherlands, that focuses on research, development and marketing of vaccines and antibodies that prevent and treat infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.